Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment
⬆️ACR20, 50, 70 response vs. pbo
⬆️secondary outcomes vs. pbo
⬆️serious AE vs. pbo, ⬆️zoster
⭐️no MACE/VTE/death reported
Abs#488
#ACR21
@RheumNow
https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t
Links:
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…
https://bit.ly/3wkmyAi
06-11-2021
